SCHEMBL2881250

SCHEMBL2881250

CCOC(=O)c1nc(C#N)c2c(c(Cl)cn2-c2ccc(OC)cc2)c1OC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 3/20 0.41
GABRB2 P47870 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPBWR1 P48145 2/20 0.41
MCHR1 Q99705 1/20 0.41
ALDH1A1 P00352 4/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
OPRK1 P41145 1/20 0.38
RAB9A P51151 1/20 0.38
PDE4D Q08499 1/20 0.38
HPGD P15428 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ADORA1 P30542 2/20 0.38
APP P05067 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP6 P55212 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883873 0.90 GABRA2 (0.45) GABRA2GABRB2SMN1; SMN2ALDH1A1MAPT
SCHEMBL2881712 0.87 GABRA2 (0.38) GABRA2GABRB2SMN1; SMN2NPBWR1MCHR1
SCHEMBL2880287 0.83 SMN1; SMN2 (0.43) GABRA2GABRB2SMN1; SMN2NPBWR1MCHR1
SCHEMBL2885998 0.80 POLB (0.39) ALDH1A1MAPTPDE4DHPGDKDM4E
SCHEMBL2884506 0.80 KDM4E (0.47) GABRA2GABRB2SMN1; SMN2ALDH1A1MAPT
SCHEMBL2889375 0.77 NPC1 (0.38) GABRA2GABRB2ALDH1A1MAPTHTT
SCHEMBL2886779 0.77 GABRA2 (0.47) GABRA2GABRB2ALDH1A1MAPTNPC1
SCHEMBL2885239 0.77 CSNK2A2 (0.35) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL2886884 0.76 SMN1; SMN2 (0.38) GABRA2GABRB2SMN1; SMN2NPBWR1ALDH1A1
SCHEMBL2886558 0.75 GNRHR (0.36) SMN1; SMN2ALDH1A1NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 GABRA2 2460/4885GABRB2 1903/4885SMN1; SMN2 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.